Expect 15-18% upside in Sun Pharma over medium to long term: Hemang Jani

May 23, 2024

Sun Pharma numbers were slightly below expectations in terms of EBITDA and we do think that though they have guided for a very strong growth through their speciality portfolio, that is a little bit time away.

More To Explore

NSE Clearing fails to meet liquidity norms; report Rs 176.65-cr shortfall amid pending dues from BSE

NSE Clearing Ltd, the clearing house of the National Stock Exchange (NSE), has failed to meet the capital markets regulator Sebi’s mandated liquidity requirements, citing

February 5, 2025

Tech View: Nifty eyes 24,050 as next target; support at 23,550 from put writing. How to trade on Thursday

Tech view: Rupak De of LKP Securities noted that the Nifty could move towards 24,050 in the near term, with support at 23,500, where maximum

February 5, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003